(Q26748733)

Europe PubMed Central

3 April 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

on focus list of Wikimedia project

27 October 2022

ScienceSource

0 references

cites work

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

9 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Molecular monitoring in CML and the prospects for treatment-free remissions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Is there a best TKI for chronic phase CML?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

The interferon-alpha revival in CML.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Managing pregnancy in chronic myeloid leukaemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Do we need more drugs for chronic myeloid leukemia?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Is going for cure in chronic myeloid leukemia possible and justifiable?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Standardized definitions of molecular response in chronic myeloid leukemia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Educational session: managing chronic myeloid leukemia as a chronic disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Chronic myelogenous leukemia stem cells: What's new?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Standardisation of molecular monitoring for chronic myeloid leukaemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Harmonization of molecular monitoring of CML therapy in Europe

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

31 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Hematology: curing CML with imatinib--a dream come true?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Statistical methods in cancer research. Volume IV. Descriptive epidemiology.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4980559

Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27133824

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.115

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2016.115

1 reference

Dimensions Publication ID

4866050

1022073613

0 references

4866050

1 reference

1 reference

1 reference